Sunovion Pharmaceuticals has announced that Mark Iwicki, formerly president and chief operating officer at Sunovion, has been appointed as the company's president and CEO. Iwicki was hired by Sepracor – Sunovion's predecessor until the company changed names in 2010 – as EVP and chief commercial officer in 2007. With more than 20 years experience in the industry, Iwicki's leadership roles have included positions with Novartis, Merck and Astra Merck Inc., and he currently serves as a board member of The Pharmaceutical Research and Manufacturers of America (PhRMA).
ImpactRx, a company dedicated to tracking, evaluating and reporting on the effects of promotional pharma activities on physician prescribing behavior, has announced the appointment of Gregory Ellis to the position of president and CEO. Ellis joins ImpactRx from Rosetta, where he was previously a senior partner at the firm since 2002 and helped the agency grow from $5 million to $240 million in annual revenue over a nine year period. With more than 30 years experience in the information, analysis and consulting market, Ellis formed his career at such market research firms as IRI, Nielsen and Opinion Research Corporation.